ESR1 and breast cancer: The combination of trastuzumab and tamoxifen treatment markedly decreased the 3D matrigel growth of the HER2+/ER+ breast cancer cells, while the AMPC inhibition of TFF3 could further decrease the 3D matrigel growth of these treated cells (Supplementary Figure 4D and 4E).